Hành vi xã hội bất thường, tăng hoạt động, giảm trí nhớ không gian xa và tăng cường tín hiệu dopaminergic trung gian D1 ở chuột thiếu gen synthase nitric oxide thần kinh
Tóm tắt
Từ khóa
Tài liệu tham khảo
Chen ZY, Jing D, Bath KG, Ieraci A, Khan T, Siao CJ, Herrera DG, Toth M, Yang C, McEwen BS, et al: Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science. 2006, 314: 140-143.
Gainetdinov RR, Mohn AR, Caron MG: Genetic animal models: focus on schizophrenia. Trends Neurosci. 2001, 24: 527-533.
Powell CM, Miyakawa T: Schizophrenia-relevant behavioral testing in rodent models: a uniquely human disorder?. Biol Psychiatry. 2006, 59: 1198-1207.
Takao K, Yamasaki N, Miyakawa T: Impact of brain-behavior phenotypying of genetically-engineered mice on research of neuropsychiatric disorders. Neurosci Res. 2007, 58: 124-132.
Zeng H, Chattarji S, Barbarosie M, Rondi-Reig L, Philpot BD, Miyakawa T, Bear MF, Tonegawa S: Forebrain-specific calcineurin knockout selectively impairs bidirectional synaptic plasticity and working/episodic-like memory. Cell. 2001, 107: 617-629.
Miyakawa T, Leiter LM, Gerber DJ, Gainetdinov RR, Sotnikova TD, Zeng H, Caron MG, Tonegawa S: Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proc Natl Acad Sci USA. 2003, 100: 8987-8992.
Gerber DJ, Hall D, Miyakawa T, Demars S, Gogos JA, Karayiorgou M, Tonegawa S: Evidence for association of schizophrenia with genetic variation in the 8p21.3 gene, PPP3CC, encoding the calcineurin gamma subunit. Proc Natl Acad Sci USA. 2003, 100: 8993-8998.
Takao K, Miyakawa T: Investigating genes-to-behaviors pathways in psychiatric disorders: An approach using a comprehensive behavioral test battery on genetically engineered mice. Ann N Y Acad Sci. 2006, 1086: 144-159.
Yamasaki N, Maekawa M, Kobayashi K, Kajii Y, Maeda J, Soma M, Takao K, Tanda K, Ohira K, Toyama K, et al: Alpha-CaMKII deficiency causes immature dentate gyrus, a novel candidate endophenotype of psychiatric disorders. Mol Brain. 2008, 1: 6-
Dawson TM, Snyder SH: Gases as biological messengers: nitric oxide and carbon monoxide in the brain. J Neurosci. 1994, 14: 5147-5159.
Zhuo M, Small SA, Kandel ER, Hawkins RD: Nitric oxide and carbon monoxide produce activity-dependent long-term synaptic enhancement in hippocampus. Science. 1993, 260: 1946-1950.
Dawson TM, Sasaki M, Gonzalez-Zulueta M, Dawson VL: Regulation of neuronal nitric oxide synthase and identification of novel nitric oxide signaling pathways. Prog Brain Res. 1998, 118: 3-11.
Bredt DS, Snyder SH: Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci USA. 1990, 87: 682-685.
Bredt DS, Glatt CE, Hwang PM, Fotuhi M, Dawson TM, Snyder SH: Nitric oxide synthase protein and mRNA are discretely localized in neuronal populations of the mammalian CNS together with NADPH diaphorase. Neuron. 1991, 7: 615-624.
Bredt DS, Ferris CD, Snyder SH: Nitric oxide synthase regulatory sites. Phosphorylation by cyclic AMP-dependent protein kinase, protein kinase C, and calcium/calmodulin protein kinase; identification of flavin and calmodulin binding sites. J Biol Chem. 1992, 267: 10976-10981.
Hayashi Y, Nishio M, Naito Y, Yokokura H, Nimura Y, Hidaka H, Watanabe Y: Regulation of neuronal nitric-oxide synthase by calmodulin kinases. J Biol Chem. 1999, 274: 20597-20602.
Dawson VL, Dawson TM, Bartley DA, Uhl GR, Snyder SH: Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures. J Neurosci. 1993, 13: 2651-2661.
Christopherson KS, Hillier BJ, Lim WA, Bredt DS: PSD-95 assembles a ternary complex with the N-methyl-D-aspartic acid receptor and a bivalent neuronal NO synthase PDZ domain. J Biol Chem. 1999, 274: 27467-27473.
Sattler R, Xiong Z, Lu WY, Hafner M, MacDonald JF, Tymianski M: Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science. 1999, 284: 1845-1848.
Huang PL, Dawson TM, Bredt DS, Snyder SH, Fishman MC: Targeted disruption of the neuronal nitric oxide synthase gene. Cell. 1993, 75: 1273-1286.
Nelson RJ, Demas GE, Huang PL, Fishman MC, Dawson VL, Dawson TM, Snyder SH: Behavioural abnormalities in male mice lacking neuronal nitric oxide synthase. Nature. 1995, 378: 383-386.
Kriegsfeld LJ, Eliasson MJ, Demas GE, Blackshaw S, Dawson TM, Nelson RJ, Snyder SH: Nocturnal motor coordination deficits in neuronal nitric oxide synthase knock-out mice. Neuroscience. 1999, 89: 311-315.
Weitzdoerfer R, Hoeger H, Engidawork E, Engelmann M, Singewald N, Lubec G, Lubec B: Neuronal nitric oxide synthase knock-out mice show impaired cognitive performance. Nitric Oxide. 2004, 10: 130-140.
Bernstein HG, Stanarius A, Baumann B, Henning H, Krell D, Danos P, Falkai P, Bogerts B: Nitric oxide synthase-containing neurons in the human hypothalamus: reduced number of immunoreactive cells in the paraventricular nucleus of depressive patients and schizophrenics. Neuroscience. 1998, 83: 867-875.
Lauer M, Johannes S, Fritzen S, Senitz D, Riederer P, Reif A: Morphological abnormalities in nitric-oxide-synthase-positive striatal interneurons of schizophrenic patients. Neuropsychobiology. 2005, 52: 111-117.
Reif A, Herterich S, Strobel A, Ehlis AC, Saur D, Jacob CP, Wienker T, Topner T, Fritzen S, Walter U, et al: A neuronal nitric oxide synthase (NOS-I) haplotype associated with schizophrenia modifies prefrontal cortex function. Mol Psychiatry. 2006, 11: 286-300.
Fallin MD, Lasseter VK, Avramopoulos D, Nicodemus KK, Wolyniec PS, McGrath JA, Steel G, Nestadt G, Liang KY, Huganir RL, et al: Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. Am J Hum Genet. 2005, 77: 918-936.
Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, Cooper GM, Nord AS, Kusenda M, Malhotra D, Bhandari A, et al: Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science. 2008, 320: 539-543.
Xu B, Wratten N, Charych EI, Buyske S, Firestein BL, Brzustowicz LM: Increased expression in dorsolateral prefrontal cortex of CAPON in schizophrenia and bipolar disorder. PLoS Med. 2005, 2: e263-
Jaffrey SR, Snowman AM, Eliasson MJ, Cohen NA, Snyder SH: CAPON: a protein associated with neuronal nitric oxide synthase that regulates its interactions with PSD95. Neuron. 1998, 20: 115-124.
Wratten NS, Memoli H, Huang Y, Dulencin AM, Matteson PG, Cornacchia MA, Azaro MA, Messenger J, Hayter JE, Bassett AS, et al: Identification of a Schizophrenia-Associated Functional Noncoding Variant in NOS1AP. Am J Psychiatry. 2009, 166 (4): 434-41.
Coyle JT: Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol. 2006, 26: 365-384.
Walaas SI, Aswad DW, Greengard P: A dopamine- and cyclic AMP-regulated phosphoprotein enriched in dopamine-innervated brain regions. Nature. 1983, 301: 69-71.
Svenningsson P, Nishi A, Fisone G, Girault JA, Nairn AC, Greengard P: DARPP-32: an integrator of neurotransmission. Annu Rev Pharmacol Toxicol. 2004, 44: 269-296.
Nishi A, Snyder GL, Greengard P: Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J Neurosci. 1997, 17: 8147-8155.
Hemmings HC, Greengard P, Tung HY, Cohen P: DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1. Nature. 1984, 310: 503-505.
Greengard P, Allen PB, Nairn AC: Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron. 1999, 23: 435-447.
King MM, Huang CY, Chock PB, Nairn AC, Hemmings HC, Chan KF, Greengard P: Mammalian brain phosphoproteins as substrates for calcineurin. J Biol Chem. 1984, 259: 8080-8083.
Halpain S, Girault JA, Greengard P: Activation of NMDA receptors induces dephosphorylation of DARPP-32 in rat striatal slices. Nature. 1990, 343: 369-372.
Nishi A, Snyder GL, Nairn AC, Greengard P: Role of calcineurin and protein phosphatase-2A in the regulation of DARPP-32 dephosphorylation in neostriatal neurons. J Neurochem. 1999, 72: 2015-2021.
Tsou K, Snyder GL, Greengard P: Nitric oxide/cGMP pathway stimulates phosphorylation of DARPP-32, a dopamine- and cAMP-regulated phosphoprotein, in the substantia nigra. Proc Natl Acad Sci USA. 1993, 90: 3462-3465.
Nishi A, Watanabe Y, Higashi H, Tanaka M, Nairn AC, Greengard P: Glutamate regulation of DARPP-32 phosphorylation in neostriatal neurons involves activation of multiple signaling cascades. Proc Natl Acad Sci USA. 2005, 102: 1199-1204.
Kiss JP, Vizi ES: Nitric oxide: a novel link between synaptic and nonsynaptic transmission. Trends Neurosci. 2001, 24: 211-215.
Gyurko R, Leupen S, Huang PL: Deletion of exon 6 of the neuronal nitric oxide synthase gene in mice results in hypogonadism and infertility. Endocrinology. 2002, 143: 2767-2774.
Takao K, Miyakawa T: Light/dark transition test for mice. J Vis Exp. 2006, 104-
Komada M, Takao K, Miyakawa T: Elevated plus maze test for mice. J Vis Exp. 2008, 1088-
Moy SS, Nadler JJ, Perez A, Barbaro RP, Johns JM, Magnuson TR, Piven J, Crawley JN: Sociability and preference for social novelty in five inbred strains: an approach to assess autistic-like behavior in mice. Genes Brain Behav. 2004, 3: 287-302.
Crawley JN: Designing mouse behavioral tasks relevant to autistic-like behaviors. Ment Retard Dev Disabil Res Rev. 2004, 10: 248-258.
Miyakawa T, Yared E, Pak JH, Huang FL, Huang KP, Crawley JN: Neurogranin null mutant mice display performance deficits on spatial learning tasks with anxiety related components. Hippocampus. 2001, 11: 763-775.
Snyder GL, Girault JA, Chen JY, Czernik AJ, Kebabian JW, Nathanson JA, Greengard P: Phosphorylation of DARPP-32 and protein phosphatase inhibitor-1 in rat choroid plexus: regulation by factors other than dopamine. J Neurosci. 1992, 12: 3071-3083.
Bibb JA, Snyder GL, Nishi A, Yan Z, Meijer L, Fienberg AA, Tsai LH, Kwon YT, Girault JA, Czernik AJ, et al: Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature. 1999, 402: 669-671.
Hsieh-Wilson LC, Benfenati F, Snyder GL, Allen PB, Nairn AC, Greengard P: Phosphorylation of spinophilin modulates its interaction with actin filaments. J Biol Chem. 2003, 278: 1186-1194.
Porsolt RD, Le Pichon M, Jalfre M: Depression: a new animal model sensitive to antidepressant treatments. Nature. 1977, 266: 730-732.
Nishi A, Bibb JA, Snyder GL, Higashi H, Nairn AC, Greengard P: Amplification of dopaminergic signaling by a positive feedback loop. Proc Natl Acad Sci USA. 2000, 97: 12840-12845.
Ahn JH, McAvoy T, Rakhilin SV, Nishi A, Greengard P, Nairn AC: Protein kinase A activates protein phosphatase 2A by phosphorylation of the B56delta subunit. Proc Natl Acad Sci USA. 2007, 104: 2979-2984.
Zhang J, Forkstam C, Engel JA, Svensson L: Role of dopamine in prepulse inhibition of acoustic startle. Psychopharmacology (Berl). 2000, 149: 181-188.
Ellenbroek BA, Lubbers LJ, Cools AR: The role of hippocampal dopamine receptors in prepulse inhibition. Eur J Neurosci. 2002, 15: 1237-1243.
Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR: Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl). 2001, 156: 117-154.
Ralph RJ, Caine SB: Dopamine D1 and D2 agonist effects on prepulse inhibition and locomotion: comparison of Sprague-Dawley rats to Swiss-Webster, 129X1/SvJ, C57BL/6J, and DBA/2J mice. J Pharmacol Exp Ther. 2005, 312: 733-741.
Ralph-Williams RJ, Lehmann-Masten V, Otero-Corchon V, Low MJ, Geyer MA: Differential effects of direct and indirect dopamine agonists on prepulse inhibition: a study in D1 and D2 receptor knock-out mice. J Neurosci. 2002, 22: 9604-9611.
Ralph-Williams RJ, Lehmann-Masten V, Geyer MA: Dopamine D1 rather than D2 receptor agonists disrupt prepulse inhibition of startle in mice. Neuropsychopharmacology. 2003, 28: 108-118.
Bilbo SD, Hotchkiss AK, Chiavegatto S, Nelson RJ: Blunted stress responses in delayed type hypersensitivity in mice lacking the neuronal isoform of nitric oxide synthase. J Neuroimmunol. 2003, 140: 41-48.
Wurbel H: Behavioral phenotyping enhanced – beyond (environmental) standardization. Genes Brain Behav. 2002, 1: 3-8.
Crusio WE: Flanking gene and genetic background problems in genetically manipulated mice. Biol Psychiatry. 2004, 56: 381-385.
Del Bel EA, Guimaraes FS, Bermudez-Echeverry M, Gomes MZ, Schiaveto-de-souza A, Padovan-Neto FE, Tumas V, Barion-Cavalcanti AP, Lazzarini M, Nucci-da-Silva LP, de Paula-Souza D: Role of nitric oxide on motor behavior. Cell Mol Neurobiol. 2005, 25: 371-392.
Maren S: Effects of 7-nitroindazole, a neuronal nitric oxide synthase (nNOS) inhibitor, on locomotor activity and contextual fear conditioning in rats. Brain Res. 1998, 804: 155-158.
Volke V, Wegener G, Bourin M, Vasar E: Antidepressant- and anxiolytic-like effects of selective neuronal NOS inhibitor 1-(2-trifluoromethylphenyl)-imidazole in mice. Behav Brain Res. 2003, 140: 141-147.
Trainor BC, Workman JL, Jessen R, Nelson RJ: Impaired nitric oxide synthase signaling dissociates social investigation and aggression. Behav Neurosci. 2007, 121: 362-369.
Volke V, Soosaar A, Koks S, Bourin M, Mannisto PT, Vasar E: 7-Nitroindazole, a nitric oxide synthase inhibitor, has anxiolytic-like properties in exploratory models of anxiety. Psychopharmacology (Berl). 1997, 131: 399-405.
Bohme GA, Bon C, Lemaire M, Reibaud M, Piot O, Stutzmann JM, Doble A, Blanchard JC: Altered synaptic plasticity and memory formation in nitric oxide synthase inhibitor-treated rats. Proc Natl Acad Sci USA. 1993, 90: 9191-9194.
Black MD, Simmonds J, Senyah Y, Wettstein JG: Neonatal nitric oxide synthase inhibition: social interaction deficits in adulthood and reversal by antipsychotic drugs. Neuropharmacology. 2002, 42: 414-420.
Shinkai T, Ohmori O, Hori H, Nakamura J: Allelic association of the neuronal nitric oxide synthase (NOS1) gene with schizophrenia. Mol Psychiatry. 2002, 7: 560-563.
O'Donovan MC, Craddock N, Norton N, Williams H, Peirce T, Moskvina V, Nikolov I, Hamshere M, Carroll L, Georgieva L, et al: Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet. 2008, 40: 1053-1055.
Tang W, Huang K, Tang R, Zhou G, Fang C, Zhang J, Du L, Feng G, He L, Shi Y: Evidence for association between the 5' flank of the NOS1 gene and schizophrenia in the Chinese population. Int J Neuropsychopharmacol. 2008, 11: 1063-1071.
Becker JT, Walker JA, Olton DS: Neuroanatomical bases of spatial memory. Brain Res. 1980, 200: 307-320.
Morris RG, Garrud P, Rawlins JN, O'Keefe J: Place navigation impaired in rats with hippocampal lesions. Nature. 1982, 297: 681-683.
Kantor DB, Lanzrein M, Stary SJ, Sandoval GM, Smith WB, Sullivan BM, Davidson N, Schuman EM: A role for endothelial NO synthase in LTP revealed by adenovirus-mediated inhibition and rescue. Science. 1996, 274: 1744-1748.
Son H, Hawkins RD, Martin K, Kiebler M, Huang PL, Fishman MC, Kandel ER: Long-term potentiation is reduced in mice that are doubly mutant in endothelial and neuronal nitric oxide synthase. Cell. 1996, 87: 1015-1023.
Wilson RI, Godecke A, Brown RE, Schrader J, Haas HL: Mice deficient in endothelial nitric oxide synthase exhibit a selective deficit in hippocampal long-term potentiation. Neuroscience. 1999, 90: 1157-1165.
Brenman JE, Chao DS, Gee SH, McGee AW, Craven SE, Santillano DR, Wu Z, Huang F, Xia H, Peters MF, et al: Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha1-syntrophin mediated by PDZ domains. Cell. 1996, 84: 757-767.
Hopper RA, Garthwaite J: Tonic and phasic nitric oxide signals in hippocampal long-term potentiation. J Neurosci. 2006, 26: 11513-11521.
Kandel ER: The molecular biology of memory storage: a dialogue between genes and synapses. Science. 2001, 294: 1030-1038.
Desai RI, Terry P, Katz JL: A comparison of the locomotor stimulant effects of D1-like receptor agonists in mice. Pharmacol Biochem Behav. 2005, 81: 843-848.
Nikulina EM, Skrinskaya JA, Popova NK: Role of genotype and dopamine receptors in behaviour of inbred mice in a forced swimming test. Psychopharmacology (Berl). 1991, 105: 525-529.
Calabresi P, Gubellini P, Centonze D, Picconi B, Bernardi G, Chergui K, Svenningsson P, Fienberg AA, Greengard P: Dopamine and cAMP-regulated phosphoprotein 32 kDa controls both striatal long-term depression and long-term potentiation, opposing forms of synaptic plasticity. J Neurosci. 2000, 20: 8443-8451.
Hoffman HS, Ison JR: Reflex modification in the domain of startle: I. Some empirical findings and their implications for how the nervous system processes sensory input. Psychol Rev. 1980, 87: 175-189.
Braff DL, Swerdlow NR, Geyer MA: Symptom correlates of prepulse inhibition deficits in male schizophrenic patients. Am J Psychiatry. 1999, 156: 596-602.
Johansson C, Jackson DM, Svensson L: Nitric oxide synthase inhibition blocks phencyclidine-induced behavioural effects on prepulse inhibition and locomotor activity in the rat. Psychopharmacology (Berl). 1997, 131: 167-173.
Klamer D, Engel JA, Svensson L: The nitric oxide synthase inhibitor, L-NAME, block phencyclidine-induced disruption of prepulse inhibition in mice. Psychopharmacology (Berl). 2001, 156: 182-186.
Klamer D, Engel JA, Svensson L: Effects of phencyclidine on acoustic startle and prepulse inhibition in neuronal nitric oxide synthase deficient mice. Eur Neuropsychopharmacol. 2005, 15: 587-590.
Schwarzkopf SB, Bruno JP, Mitra T: Effects of haloperidol and SCH 23390 on acoustic startle and prepulse inhibition under basal and stimulated conditions. Prog Neuropsychopharmacol Biol Psychiatry. 1993, 17: 1023-1036.
Hoffman DC, Donovan H: D1 and D2 dopamine receptor antagonists reverse prepulse inhibition deficits in an animal model of schizophrenia. Psychopharmacology (Berl). 1994, 115: 447-453.
Zhuang X, Oosting RS, Jones SR, Gainetdinov RR, Miller GW, Caron MG, Hen R: Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc Natl Acad Sci USA. 2001, 98: 1982-1987.
Ralph-Williams RJ, Paulus MP, Zhuang X, Hen R, Geyer MA: Valproate attenuates hyperactive and perseverative behaviors in mutant mice with a dysregulated dopamine system. Biol Psychiatry. 2003, 53: 352-359.